122 related articles for article (PubMed ID: 36206607)
1. The use of a topical protease inhibitor, Saquinavir, to alleviate mouse papillomavirus-mediated anal disease.
Gunder LC; Johnson HR; Green HA; Bilger A; Moyer TH; Zhang W; Ziolkowski MR; Bertrang PA; Carchman EH
Virology; 2022 Nov; 576():96-104. PubMed ID: 36206607
[TBL] [Abstract][Full Text] [Related]
2. Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease.
Gunder LC; Johnson HR; Yao E; Moyer TH; Green HA; Sherer N; Zhang W; Carchman EH
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112993
[TBL] [Abstract][Full Text] [Related]
3. A Novel Model for Papillomavirus-Mediated Anal Disease and Cancer Using the Mouse Papillomavirus.
Blaine-Sauer S; Shin MK; Matkowskyj KA; Ward-Shaw E; Lambert PF
mBio; 2021 Aug; 12(4):e0161121. PubMed ID: 34281391
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models.
Gunder LC; Blaine-Sauer S; Johnson HR; Shin MK; Auyeung AS; Zhang W; Leverson GE; Ward-Shaw ET; King RE; McGregor SM; Matkowskyj KA; Lambert PF; Carchman EH
Viruses; 2022 Jul; 14(8):. PubMed ID: 35893697
[TBL] [Abstract][Full Text] [Related]
5. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
6. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
[TBL] [Abstract][Full Text] [Related]
8. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
9. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
[TBL] [Abstract][Full Text] [Related]
10. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
12. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.
Brunet C; Reliquet V; Jovelin T; Venisse N; Winer N; Bui E; Le Moal G; Perfezou P; De Saint Martin L; Raffi F
Med Mal Infect; 2012 Sep; 42(9):421-8. PubMed ID: 22938775
[TBL] [Abstract][Full Text] [Related]
14. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
16. Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer.
Rademacher BL; Matkowskyj KA; LaCount ED; Carchman EH
Eur J Cancer Prev; 2019 Nov; 28(6):483-491. PubMed ID: 30888976
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors.
Gatanaga H; Aizawa S; Kikuchi Y; Tachikawa N; Genka I; Yoshizawa S; Yamamoto Y; Yasuoka A; Oka S
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1493-8. PubMed ID: 10580399
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.
Lopez-Cortes LF; Ruiz-Valderas R; Rivero A; Camacho A; Marquez-Solero M; Santos J; García-Lazaro M; Viciana P; Rodriguez-Baños J; Ocampo A
Ther Drug Monit; 2007 Apr; 29(2):171-6. PubMed ID: 17417070
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.
Bucher HC; Bichsel M; Taffé P; Furrer H; Telenti A; Hirschel B; Weber R; Bernasconi E; Vernazza P; Minder C; Battegay M;
HIV Med; 2002 Oct; 3(4):247-53. PubMed ID: 12444942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
